[Source: https://seekingalpha.com/news/3320185-biondvax-can-continue-late-stage-flu-vaccine-trial]

By  | December 27, 2017

  • BiondVax (NASDAQ:BVXV) will proceed with its Phase 3 trial plan for its flu vaccine M-001 after receiving advice from a European Medicines Agency committee.
  • The Committee for Medicinal Products for Human Use agreed to the study design and said “a single pivotal efficacy trial that provides a robust demonstration of efficacy against laboratory-proven influenza like illness could suffice for an approval.”
  • The trial will take place in Eastern Europe and start before the 2018/19 flu season.
  • BiondVax shares are up 3.2%.
  • Previously: Biondvax Pharmaceuticals reports Q3 results (Nov. 28)